Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2492 • 2016 ACR/ARHP Annual Meeting
Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
Peter C. Taylor¹, Rieke Alten², Juan Jesus Gomez-Reino³, Roberto Caporali⁴, Philippe Bertin⁵, Laura Grant⁶, Elaine Brohan⁶, Jane Wells⁶, Radu Vasilescu⁷ and Miriam Tarallo⁸, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Charité University Medicine, Berlin, Germany, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Università di Pavia, Pavia, Italy, ⁵Rheumatology, CHU Dupuytren, Limoges, France, ⁶Adelphi Values, Bollington, United Kingdom, ⁷Medical Affairs, Pfizer, Brussels, Belgium, ⁸GHV, Pfizer, Rome, Italy
Background/Purpose: The high prevalence and significant burden of RA has led to the development of a wide variety of treatments; specifically, conventional synthetic DMARDs, and…
Abstract Number: 558 • 2016 ACR/ARHP Annual Meeting
Clinical, Sonographic and Immunological Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study with 12 Months of Follow-up
Julio Ramírez¹, Andrea Cuervo², Jose Antonio Narváez³, Virginia Ruiz-Esquide², Javier Hernández-Gañán³, Raquel Celis⁴, Jose Inciarte-Mundo², M. Victoria Hernández², Jose L. Pablos⁵, Raimon Sanmarti² and Juan D. Cañete², ¹Rheumatology, Hospital Clínic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Radiology, Hospital Bellvitge, Barcelona, Spain, ⁴Rheumatology, Arthritis Unit, Barcelona, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose: To determine clinical, sonographic and immunological biomarkers predicting structural damage progression at 12 months of follow-up as measured by Magnetic Resonance Imaging (MRI) in a…
Abstract Number: 1566 • 2016 ACR/ARHP Annual Meeting
Histone Lysine Methylation and STAT3 Differentially Regulate Constitutive and IL-6-Induced MMPs Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki^1,2, Takuma Tsuzuki Wada^2,3, Yoshimi Aizaki^1,2, Kazuhiro Yokota¹, Hiroshi Kajiyama¹, Yu Funakubo Asanuma¹, Kojiro Sato¹, Hiromi Oda⁴ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ⁴Orthopedic Surgery, Faculty of Medicine, Saitama Medical Univeristy, Morohongo Moroyama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes progressive joint destruction. In spite of the modern medications, including biologic reagents, it…
Abstract Number: 2503 • 2016 ACR/ARHP Annual Meeting
Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study
Iris Navarro-Millán¹, Ronan O'Beirne², Melanie Morris³, Bernadette Johnson¹, James Willig⁴, Huifeng Yun⁵, Andrea Cherrington⁶, Liana Fraenkel⁷, Monika M. Safford⁸ and Jeffrey Curtis⁹, ¹Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Continuing Medical Education, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Yale University School of Medicine, New Haven, CT, ⁸Weill Cornell Medical College, New York, NY, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Little is known on what subjective or objective data that rheumatologists consider most important for them to inform their treatment decisions for patients…
Abstract Number: 561 • 2016 ACR/ARHP Annual Meeting
Sodium Intake Is Increased in Patients with Early Rheumatoid Arthritis and Is Associated with Radiographic Erosions
sarah marouen¹, Guilhem du Cailar², Rachel Audo³, Cédric Lukas⁴, Gaelle Vial⁵, Anne Tournadre⁶, Emmanuel Barrat⁷, Jean Ribstein², Bernard Combe⁸, Jacques Morel⁹ and Claire I. Daien¹⁰, ¹Rhumatology Department, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ³Rheumatology, Teaching Hospital of Lapeyronie, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology, Gabriel Montpied Hospital and Clermont Ferrand University, Clermont Ferrand, France, ⁶Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Recherche et Développement, Laboratoire Lescuyer, AYTRE, France, ⁸Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁹Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ¹⁰Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease resulting from an interaction between genetic and environmental factors. Recently, sodium intake was suggested as a risk…
Abstract Number: 1582 • 2016 ACR/ARHP Annual Meeting
Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
Alan Slade¹, Phillip Koo¹, Yanling He², Pascal Espie³, Anita Auger-Sarrazin³, James S. Rush³ and Peter Gergely³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Novartis Pharmaceuticals Corporation, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, Basel, Switzerland
Background/Purpose: Aberrant CD40-CD154 pathway signaling has been linked to pathology in autoimmune disease. Blocking the CD40-CD154 pathway prevents T cell-dependent antibody responses, germinal center formation…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 577 • 2016 ACR/ARHP Annual Meeting
TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells
Naonori Hashimoto¹, Kohsuke Yoshida¹, Teppei Hashimoto², Ayako Nakai¹, Kenta Kaneshiro¹, Kohjin Suzuki¹, Yoshiko Kawasaki², Nao Shibanuma³, Natsuko Nakagawa⁴, Yoshitada Sakai⁵ and Akira Hashiramoto⁶, ¹Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, ³Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁴Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, ⁵Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: DNA is fragmented and released into blood circulation as a circulating cell-free DNA (ccfDNA) because of damage or death of cells. Although the…
Abstract Number: 1593 • 2016 ACR/ARHP Annual Meeting
Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Natalia V. Zamora¹, Jean Tayar², Maria A. Lopez-Olivo³, Robin Christensen⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁵Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Baricitinib is a small molecule inhibitor of the Janus kinase (JAK) pathways that reduce and modulate the production of inflammatory mediators and cytokines. We…
Abstract Number: 2509 • 2016 ACR/ARHP Annual Meeting
Implementation of the Treat to Target Concept in Evaluation of Rheumatoid Arthritis Patients
Devy Zisman^1,2, Shirly Oren³, T. Reitblat⁴, Merav Lidar⁵, Alexandra Balbir-Gurman⁶, Itzhak A. Rosner⁷, Joy Feld², Nimer Halabi⁸, Sameer Kassem⁸ and Ori Elkayam⁹, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁴Barzilai Medical Center, Ashkelon, Israel, ⁵Medicine F, Sheba Medical Center, Ramat Gan, Israel, ⁶B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁷Bnai Zion Medical Center, Haifa, Israel, ⁸Internal Medicine, Carmel Medical Center, Haifa, Israel, ⁹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: To assess the implementation of the treat to target (T2T) concept in rheumatoid arthritis (RA) patients. Methods: Academic rheumatology units were invited to participate…
Abstract Number: 617 • 2016 ACR/ARHP Annual Meeting
Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs
Maria A. Lopez-Olivo¹, Aliza Matusevich^2,3 and Maria Suarez-Almazor⁴, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The University of Texas, School of Public Health, Houston, TX, ⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Up to one-third of the patients who receive TNFi lose responsiveness over time. Options available to these patients include treatment with an alternative TNFi…
Abstract Number: 1602 • 2016 ACR/ARHP Annual Meeting
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
Janet Pope¹, Edward Keystone², Shahin Jamal³, Lisy Wang⁴, Lara Fallon⁵, John Woolcott⁵, Irina Lazariciu⁶ and Boulos Haraoui⁷, ¹Western University, London, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Canada, Montreal, QC, Canada, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Open-label, long-term extension (LTE) studies enrolled tofacitinib-treated patients (pts) to evaluate safety and…
Abstract Number: 2517 • 2016 ACR/ARHP Annual Meeting
Long-Term Stability of the 5-Item Compliance Questionnaire Rheumatology As a Measure of Adherence in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Mary Bell², Charles H. Goldsmith³, Imy Chiu⁴, Anna Gutlin⁴ and Sharron Sandhu⁵, ¹Division of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Simon Fraser University, Vancouver, BC, Canada, ⁴Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for optimal monitoring…
Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
Abstract Number: 621 • 2016 ACR/ARHP Annual Meeting
Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Catalin Codreanu¹, Klara Sirova², Katerina Jarosova³ and Anastas Batalov⁴, ¹Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Revmatologie, Revmatologie MU Dr. Klara Sirova, sro, Ostrava, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Medical University of Plovdiv, UMHAT Kaspela, Plovdiv, Bulgaria
Background/Purpose: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, the high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].